Pre-Surgery If Needed for Oesophageal Cancer

Esophageal Cancer Clinical Trial

— preSINO  

Official title:

Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: the preSINO Trial (Pre-Surgery If Needed for Oesophageal Cancer)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03937362
• Other study ID #: Chest201902
• Status: Recruiting
• Start date: August 8, 2019
• Est. completion date: August 8, 2022

Study information

• Verified date: August 2019
• Source: Shanghai Chest Hospital
• Contact: Xiaobin Zhang, MD
• Phone: 18516302162
• Email: zxb5212[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prospective, multi-centre, diagnostic cohort study investigating the accuracy of positron emission tomography with computed tomography (PET-CT), endoscopic bite-on-bite biopsies and endoscopic ultrasonography (EUS) with fine-needle aspiration (FNA) for detecting residual disease after neoadjuvant chemoradiotherapy in patients with potentially curable esophageal squamous cell carcinoma (SCC).

Description:

After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high pathologically complete response (pCR) rates are being achieved in patients with squamous cell carcinoma (SCC). An active surveillance strategy has been proposed for SCC patients with clinically complete response (cCR) after nCRT. To justify omitting surgical resection, patients with residual disease should be accurately identified.

The objective of this study is to assess the accuracy of response evaluations after nCRT based on the preSANO trial, including positron emission tomography with computed tomography (PET-CT), endoscopic bite-on-bite biopsies and endoscopic ultrasonography (EUS) with fine-needle aspiration (FNA) in patients with potentially curable esophageal SCC.

Operable esophageal SCC patients who are planned to undergo nCRT according to the CROSS regimen and are planned to undergo surgery will be recruited from four Asian centers. Four to six weeks after completion of nCRT, patients will undergo a first clinical response evaluation (CRE-1) consisting of endoscopic bite-on-bite biopsies. In patients without histological evidence of residual tumor (i.e. without positive biopsies), surgery will be postponed another six weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT, consisting of PET-CT, endoscopic bite-on-bite biopsies and EUS with FNA. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy. Results of CRE-1 and CRE-2 as well as results of single diagnostic modalities will be correlated to pathological response in the resection specimen for calculation of sensitivity, specificity, negative predictive value and positive predictive value.

If the current study shows that major residual disease (>10% residual carcinoma at the primary tumor site and any residual nodal disease) can be accurately (i.e. with sensitivity of 80.5%) detected in patients with esophageal SCC, a prospective trial will be conducted comparing active surveillance with standard esophagectomy in patients with a clinically complete response after nCRT (SINO trial).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: August 8, 2022
• Est. primary completion date: August 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion criteria are:

1. Histologically confirmed esophageal squamous cell carcinoma;

2. Tumor located in the chest;

3. Clinical stage cT1N1-2M0, cT2-4aN0-2M0, according to the 8th Edition of the AJCC TNM classification for Esophageal Cancer;

4. Age > 20 at the date of informed consent;

5. Eastern Cooperative Oncology Group (ECOG) Performance Status of two or less;

6. Considered fit to undergo nCRT followed by surgical resection;

7. Expected survival time more than three months;

8. Written informed consent by the patient.

Exclusion criteria are:

1. Patient with a second primary tumor;

2. Previous major surgery in the chest or upper abdomen;

3. Tumor not 18F-FDG-avid at baseline PET-CT;

4. Suspected positive lymph nodes that cannot be covered by an uninterrupted radiation field that also includes the primary tumor area;

5. Primary (early) lesion already removed by EMR/ESD;

6. Previous history of chemotherapy and/or radiation therapy;

7. Cervical esophageal cancer.

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Esophageal Squamous Cell Carcinoma

Intervention

Diagnostic Test:
• First clinical response evaluation (CRE-1)
Consisting of: endoscopy with bite-on-bite biopsies
• Second clinical response evaluation (CRE-2)
Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA

Locations

Country	Name	City	State
China	Shanghai Chest Hospital	Shanghai
China	Tianjin Medical University Cancer Institute and Hospital	Tianjin
Hong Kong	Queen Mary Hospital	Hong Kong
Taiwan	Chang Gung Memorial Hospital	Linkou

Sponsors (4)

Lead Sponsor	Collaborator
Shanghai Chest Hospital	Chang Gung Memorial Hospital, Queen Mary Hospital, Hong Kong, Tianjin Medical University Cancer Institute and Hospital

Countries where clinical trial is conducted

China,  Hong Kong,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of clinical response evaluations for detecting substantial residual locoregional disease	The diagnostic performance in terms of sensitivity and specificity of both CRE-1 and CRE-2 for detecting TRG 3-4 residual tumor (more than 10% residual carcinoma) or TRG 1-2 residual tumor (less than 10% residual carcinoma) with residual nodal disease (ypN+) in the surgical resection specimen.	10-12 weeks after completion of neoadjuvant chemoradiotherapy
Secondary	Accuracy of clinical response evaluations for detecting any residual locoregional disease	The diagnostic performance in terms of sensitivity and specificity of both CRE-1 and CRE-2 for detecting pathologically non-complete response in both the primary tumor and the regional lymph nodes (TRG2-4 or ypN+).	10-12 weeks after completion of neoadjuvant chemoradiotherapy